Previous studies have shown that immune evasion is a hallmark of cancer, and the modulation of immune responses by tumor cells can significantly impact patient prognosis.[42,43] Therefore, understanding the interplay between ACTR3 expression and immune cell dynamics could inform the development of immunotherapeutic strategies aimed at enhancing antitumor immunity in CESC patients. Here, ACTR3 is linked to cervical squamous cell carcinoma.